Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669136 | 1.00 | HTR2A (0.43) | HTR2AHTR2CPDE7A | |
| Hydrochloric Acid SCHEMBL28659394 | 0.98 | HTR2A (0.46) | HTR2AHTR2CPDE7A | |
| SCHEMBL25155857 | 0.81 | HTR2A (0.34) | HTR2AHTR2CPDE7A | |
| SCHEMBL8518646 | 0.75 | CYP3A4 (0.43) | — | |
| SCHEMBL19814601 | 0.75 | ALOX15 (0.43) | — | |
| SCHEMBL14197705 | 0.73 | KDM1A (0.35) | — | |
| SCHEMBL24582723 | 0.73 | TAAR1 (0.37) | — | |
| SCHEMBL2336569 | 0.73 | HDAC4 (0.43) | — | |
| SCHEMBL23232266 | 0.73 | OPRL1 (0.42) | HTR2AHTR2CPDE7A | |
| SCHEMBL1604324 | 0.73 | HDAC4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12286433-B1 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12281115-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12240848-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12116366-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240254124-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-8119681-B2 | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119681-B2 | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2091922-B1 | 2-[1-PHENYL-5-HYDROXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
| CN-101528707-A | 2- [ 1-phenyl-5-hydroxy or methoxy-4 alpha-methyl-hexahydrocyclopenta [ f ] indazol-5-yl ] ethylphenyl derivatives useful as glucocorticoid receptor ligands | MERCK & CO INC (US) | 2009-09-09 | — | — | CN | disclosed |
| WO-2008051532-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-12240848-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-12281115-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20240254124-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | HTR2A 673/4885HTR2C 463/4885PDE7A 109/4885 |
| US-12116366-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | HTR2A 2804/4885HTR2C 2055/4885PDE7A 3195/4885 |
| US-12286433-B1 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | HTR2A 649/4885HTR2C 367/4885PDE7A 432/4885 |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | HTR2A 3051/4885HTR2C 3174/4885PDE7A 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.